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TDF/FTC+ATV/r, £85,477 for ABC/3TC+EFV, and £99,609 for ABC/3TC+ATV/r. At a will-
ingness-to-pay threshold of £30,000 per QALY gained, TDF/FTC-based regimens were 
predicted to be cost-effective compared with ABC/3TC-based regimens, with incre-
mental cost-effectiveness ratios of £20,545 for TDF/FTC+EFV versus ABC/3TC+EFV 
and £20,652 for TDF/FTC+ATV/r versus ABC/3TC+ATV/r. In subgroup analyses, TDF/
FTC-based regimens were predicted to yield more QALYs and to remain cost-effec-
tive compared with ABC/3TC-based regimens. ConClusions: In an analysis of 
the regimens examined in the ACTG 5202 clinical trial for treatment-naïve adults 
with HIV-1 infection, regimens containing TDF/FTC yielded more favorable health 
outcomes and were predicted to be cost-effective compared with regimens con-
taining ABC/3TC.
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objeCtives: The current recommendations for hepatitis C infection genotype 1 
include one protease inhibitor (IP), boceprevir or telaprevir, in addition to the pre-
vious standard dual therapy (DT) (peginterferon plus ribavirin). However, the cost 
of these new drugs imposes high financial burden in the health care systems. The 
aim of this study is to undertake a systematic review of the cost-effectiveness of 
boceprevir compared to telaprevir and DT. Methods: A systematic search was 
conducted in MEDLINE, EMBASE, Econlit and NHS-EED. Only full-text published 
manuscripts were considered and no further restriction were included. Relevant 
studies were selected by two independent researchers. Disagreements were resolved 
by discussion. A checklist was applied based on the CHEERS guideline to assess 
the quality of the studies. Results: Nine studies were found. Three compared 
Boceprevir versus DT whereas 6 compared both IP with DT. Six analyses were pre-
sented for naïve (no previously treated) patients and 5 analyses for patients previ-
ously treated. Comparators vary in terms of the schemes used and stopping rules 
applied. All studies modeled the disease properly. However, important differences 
in assumptions and parameters were found. Most studies adopted a national health 
system perspective. Only two studies used information from mixed treatment com-
parisons to be incorporated into the model. 8 out of 9 studies concluded that the IP 
is cost-effective for their corresponding jurisdiction. In naïve patients, two studies 
reported Telaprevir being cost-effective against Boceprevir and no study favored 
Boceprevir. In patients previously treated one study favors Boceprevir and two stud-
ies favors Telaprevir. ConClusions: The treatment with IP compared with DT is 
cost-effective in most jurisdictions where it has been evaluated. However, important 
variations were found in terms of patient´s subgroups and schemes of treatment. 
It cannot be concluded that one drug is more cost-effective than the other due to 
important structural uncertainty.
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objeCtives: Conduct a pharmacoeconomic analysis, cost-minimization type of 
therapy with linezolid in patients hospitalized between August, 2009 and December, 
2010 in a public hospital in Brazil. Methods: We conducted a retrospective cohort 
study at a Brazilian public hospital from August 1, 2009 through December 31, 2010. 
A cost-minimization analysis was undertaken for which patients used linezolid 
during the internment in this period, from the perspective of the Brazilian public 
health system. Results: The medical records of 61 patients were evaluated. Of all 
patients, 67.2% were male and mean age was 43.2 ± 17.8 years. The therapy with lin-
ezolid lasted 10.6 ± 4.7 days. The antibiogram was present in 65.6% of the records. In 
50.8% of cases, the bacteria were sensitive to linezolid. The main reason for the use 
of antibiotics was sepsis and nosocomial pneumonia (34.4% each). Sixteen (26.2%) 
patients met the criteria for changing the route of administration of the antimi-
crobial. Altogether, the cost of treatment with linezolid for these 16 patients was 
US$ 39.755,05. If it were adopted sequential therapy, the treatment would cost US$ 
31.744,28, which represents a saving of US$ 8.010,77 to the hospital. ConClusions: 
The results demonstrated the importance of pharmacoeconomic analysis of lin-
ezolid to the hospital, because in 17 months of cost analysis, these could have 
been reduced by 20,2% only with the switch antibiotic therapy. It is expected that 
results of studies such as this may contribute to the rational use of antimicrobials 
and resources for hospitals.
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objeCtives: Ontario, Canada, immunizes against influenza using a trivalent 
inactivated influenza vaccine (IIV3) under a Universal Influenza Immunization 
Program (UIIP). The UIIP offers IIV3 free of charge to all Ontarians over 6 months 
of age. A newly approved quadrivalent inactivated influenza vaccine (IIV4) offers 
wider protection against influenza B disease. In this study, we explore the expected 
cost-utility and budget impact of replacing IIV3 with IIV4 within the context of 
Ontario’s UIIP. Methods: We developed a model based on Ontario outcomes data 
published by Kwong and colleagues. We used Ontario based health care costs and 
Canadian based labor costs. Efficacy of IIV3 and IIV4 were estimated in a similar 
manner to a previous publication by Reed and colleagues. However, we improved 
by including emerging data from new meta-analyses on the efficacy of IIV3. These 
include new estimates of cross protection against mismatched B influenza offered 
by IIV3, as well as, new estimates of the vaccine efficacy in seniors. Conservatively, 
herd protection was not considered. Results: Over an average influenza season, 
caspofungin group were 74.9%,68.3%,70.2%, respectively; total costs were $8650.1, 
$10146.3, $9744.6, respectively. Thus, the cost-effectiveness ratio were 115.5, 148.6, 
138.8, respectively. ConClusions: Micafungin 100 mg/d group is the most cost-
effective option in the treatment of invasive Candida infection in China, followed 
by caspofungin group.
PIN62
ECoNomIC valuE of usINg aNtImICrobIal CoatEd suturEs for 
abdomINal INCIsIoNs to PrEvENt surgICal sItE INfECtIoNs
Singh A.1, Bartsch S.M.2, Muder R.R.3, Lee B.Y.2
1University of Pittsburgh, Pittsburgh, PA, 2Johns Hopkins Bloomberg School of Public Health, 
Baltimore, PA, 3Veterans Affairs Medical Center, Pittsburgh, PA, USA
objeCtives: Since surgical site infections (SSI) continue to impose a substantial 
burden to hospital and society, there is a need to evaluate newer SSI-prevention 
interventions such as antimicrobial (e.g., triclosan) coated sutures. Methods: We 
developed a decision analytic model using TreeAge Pro to determine the cost-effec-
tiveness of antimicrobial sutures in abdominal incisions from the hospital, third 
party payer, and societal perspectives. Sensitivity analyses systematically varied the 
risk of developing an SSI (range: 5% - 20%), cost of triclosan-coated sutures (range: $5 
- $25 per inch), and efficacy of triclosan-coated sutures to prevent infection (range: 
5% - 50%). Results: Depending on their efficacy, triclosan-coated sutures saved 
$4,109 – 13,975 (from the hospital perspective), $4,133 – 14,297 (third party payer), 
and $40,127 – 53,244 (societal) per SSI prevented, when a surgery had a 15% SSI risk. 
However, if the SSI risk after surgery was ≤ 5% and the efficacy in preventing SSIs 
was ≤ 10%, triclosan-coated sutures resulted in extra expenditure for hospitals and 
third party payers; resulting in extra costs of $1,626 and $1,071 per SSI prevented 
for hospitals and third party payers respectively, if SSI risk was 5% and efficacy was 
10%. ConClusions: Our results show that switching to triclosan-coated sutures 
from the uncoated sutures can prevent SSIs and save substantial costs to hospitals, 
third party payers, and society over a wide range of SSI prevention efficacy, cost, 
and risk values.
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objeCtives: Vaccines have been the main global means to minimize the impact of 
influenza and are recommended by WHO for individuals aged 65 years or older. The 
primary goal of influenza vaccination in the elderly is to reduce the risk of compli-
cations. Since 1998, a public-funded trivalent influenza vaccine (TIV) vaccination 
program has been implemented by the Taiwan government targeting people aged 
over 65 years. Another proposed alternative for preventing seasonal influenza is 
quadrivalent influenza vaccine (QIV) which contains two influenza A-lineages and 
two influenza B-lineages. The aim of the study is to assess, from the governmental 
perspective, the cost-effectiveness of adopting QIV versus TIV for the elderly aged 
65 years or older. Methods: A Markov model was used to estimate the cost and 
effectiveness of QIV and TIV in the elderly. Direct cost data was obtained from the 
Taiwan National Health Insurance claims data. Vaccine efficacy and coverage rate 
were based on government statistical reports. Outcomes of lifetime included cases, 
utilizations, and deaths avoided and QALYs gained. The corresponding incremental 
cost-effectiveness ratios (ICERs) were also estimated. The discount rate of cost and 
effectiveness was set at 3.5%. Results: Compared to TIV, adopting QIV would yield 
the influenza-related outcomes as follows: 26,319 influenza cases avoided, 26,021 
cases of outpatient visit avoided, 2,771 cases of influenza complication avoided, and 
330 deaths avoided. Using QIV instead of TIV would bring an additional 19,310,320 
QALYs at an extra cost of US$223.39 billion, yielding an ICER of US$35,851.3 per QALY 
gained. When herd protection of vaccination is considered, the ICER would reduce 
to US$32,660.1 per QALY gained. ConClusions: To use QIV as an alternative of 
first-line strategy to prevent seasonal influenza for the elderly in Taiwan would be 
cost-effectiveness from the governmental perspective.
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objeCtives: To assess the cost-effectiveness of the four comparators examined 
in the ACTG 5202 clinical trial, tenofovir/emtricitabine (TDF/FTC) or abacavir/
lamivudine (ABC/3TC) in combination with efavirenz (EFV) or atazanavir/ritonavir 
(ATV/r), for treatment-naïve adults with HIV-1 infection in the United Kingdom 
(UK). Methods: A Markov model with six health states based on CD4+ cell-count 
ranges was developed to estimate costs and health outcomes for individuals on first-
line therapy. Head-to-head efficacy data (lack of regimen failure and mean CD4+ cell-
count changes) up to 192 weeks for TDF/FTC+EFV, TDF/FTC+ATV/r, ABC/3TC+EFV, 
and ABC/3TC+ATV/r were obtained from the ACTG 5202 clinical trial. Antiretroviral 
drug costs were based on current list prices. Utility values, mortality, and other 
direct medical costs (2012 UK pounds) were stratified by CD4+ cell-count range 
and obtained from published sources. All outcomes were discounted at 3.5% per 
year. Sensitivity and subgroup analyses were conducted, including analysis of low 
(< 100,000 copies/mL) and high (≥ 100,000 copies/mL) baseline viral load. Results: 
Individuals using TDF/FTC-based regimens were predicted to remain on first-line 
therapy longer and accrue more QALYs than individuals using ABC/3TC-based regi-
mens (QALYs: 6.30 for TDF/FTC+EFV, 6.45 for TDF/FTC+ATV/r, 5.02 for ABC/3TC+EFV, 
and 5.26 for ABC/3TC+ATV/r). Costs were £111,882 for TDF/FTC+EFV, £124,302 for 
